Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management (Q34205665)

31 July 2017

1 reference

title

Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management (English)

1 reference

31 July 2017

main subject

polymyalgia rheumatica

1 reference

1 reference

Jean Schmidt

1

1 reference

31 July 2017

Kenneth J Warrington

series ordinal

2

1 reference

31 July 2017

publication date

1 August 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

28

1 reference

31 July 2017

issue

8

1 reference

31 July 2017

page(s)

651-666

1 reference

https://scigraph.springernature.com/pub.10.2165/11592500-000000000-00000

31 July 2017

exact match

0 references

cites work

Epidemiology of giant cell arteritis and polymyalgia rheumatica

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Medium- and large-vessel vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county. A prospective investigation, 1982-1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Epidemiology of biopsy proven giant cell arteritis in northwestern Spain: trend over an 18 year period

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis in Jerusalem: a 12-year epidemiological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis in northwestern Spain: a 25-year epidemiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Disease patterns and tissue cytokine profiles in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Immunopathways in giant cell arteritis and polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Scalp necrosis in giant cell arteritis and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Headache in giant cell arteritis and other arteritides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis and visual loss. A 3-year retrospective hospital investigation in a Danish county

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Neurologic complications of giant cell (temporal) arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Tongue necrosis as first symptom of giant cell arteritis (GCA).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Large-vessel involvement in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Symptomatic lower extremity vasculitis in giant cell arteritis: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Fever of unknown origin in adults: evaluation of 144 cases in a non-university hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis: validity and reliability of various diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Disease pattern in cranial and large-vessel giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Healed or quiescent temporal arteritis versus senescent changes in temporal artery biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Surgical pathology of noninfectious ascending aortitis: a study of 45 cases with emphasis on an isolated variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Color duplex ultrasonography in the diagnosis of temporal arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Diagnostic value of T2-weighted imaging for the detection of superficial cranial artery inflammation in giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Long-term follow-up of aortic involvement in giant cell arteritis: a series of 48 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

PET features of aortic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Polymyalgia rheumatica: a 10-year epidemiologic and clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Medical management of polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Ultrasonographic monitoring of response to therapy in polymyalgia rheumatica.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Evidence for a different anatomic basis for joint disease localization in polymyalgia rheumatica in comparison with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

An evaluation of criteria for polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Does this patient have temporal arteritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

EULAR recommendations for the management of large vessel vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Experience with infliximab (anti-TNF monoclonal antibody) as monotherapy for giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Antiplatelet and anticoagulant therapy in patients with giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Therapeutic effects of acetylsalicylic acid in giant cell arteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Prognosis of large-vessel giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Improving therapeutic options for patients with giant cell arteritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Horton's disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592500-000000000-00000

Contribution of muscle weakness to postural instability in the elderly. A systematic review

21 January 2018

1 reference

12 December 2020

Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association.

1 reference

12 December 2020

Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy.

1 reference

12 December 2020

Giant cell arteritis: Involvement of intracranial arteries

1 reference

12 December 2020

Long-term follow-up of polymyalgia rheumatica: evidence for synovitis

1 reference

12 December 2020

Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients

1 reference

12 December 2020

18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans

1 reference

12 December 2020

Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan

1 reference

12 December 2020

Effect of biopsy length on the rate of positive temporal artery biopsies

1 reference

12 December 2020

Inflammatory changes of hip synovial structures in polymyalgia rheumatica

1 reference

12 December 2020

A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).

1 reference

12 December 2020

Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study

1 reference

12 December 2020

Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality.

1 reference

12 December 2020

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial

1 reference

12 December 2020

Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate

1 reference

12 December 2020

Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial

1 reference

12 December 2020

Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy

1 reference

12 December 2020

The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain

1 reference

12 December 2020

Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis.

1 reference

12 December 2020

Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey.

1 reference

12 December 2020

How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?

1 reference

12 December 2020

Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis

1 reference

12 December 2020

High incidence of polymyalgia rheumatica and giant cell arteritis in a Swedish community

1 reference

12 December 2020

Giant cell arteritis with a low erythrocyte sedimentation rate: comments on the article by Salvarani and Hunder

1 reference

12 December 2020

Relapse in a population based cohort of patients with polymyalgia rheumatica.

1 reference

12 December 2020

Analysis of temporal artery biopsies in an 18-year period at a community hospital

1 reference

12 December 2020

Polymyalgia rheumatica and giant-cell arteritis

1 reference

12 December 2020

Head-and-neck swelling: an under-recognized feature of giant cell arteritis. A report of 37 patients.

1 reference

12 December 2020

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis

1 reference

12 December 2020

Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity

1 reference

12 December 2020

Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis

1 reference

12 December 2020

Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report on nineteen cases

1 reference

12 December 2020

Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study

1 reference

12 December 2020

The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual and seasonal fluctuations.

1 reference

12 December 2020

A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.

1 reference

12 December 2020

Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort

1 reference

12 December 2020

Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis

1 reference

12 December 2020

Polymyalgia rheumatica

1 reference

12 December 2020

Comparison of extracapsular changes by magnetic resonance imaging in patients with rheumatoid arthritis and polymyalgia rheumatica

1 reference

12 December 2020

Clinical characteristics of polymyalgia rheumatica in Japanese patients: evidence of synovitis and extracapsular inflammatory changes by fat suppression magnetic resonance imaging

1 reference

12 December 2020

Peripheral musculoskeletal manifestations in polymyalgia rheumatica

1 reference

12 December 2020

Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis.

1 reference

12 December 2020

Visual hallucinations in giant cell arteritis: association with visual loss

1 reference

12 December 2020

Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids.

1 reference

12 December 2020

The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.

1 reference

12 December 2020

Scalp necrosis in giant cell arteritis

1 reference

12 December 2020

Risk factors and predictive models of giant cell arteritis in polymyalgia rheumatica

1 reference

12 December 2020

Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica

1 reference

12 December 2020

Treatment of longstanding active giant cell arteritis with infliximab: report of four cases

1 reference

12 December 2020

Increase in age at onset of giant cell arteritis: a population-based study

1 reference

12 December 2020

Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica

1 reference

12 December 2020

Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial

1 reference

12 December 2020

Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study

1 reference

12 December 2020

Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions

1 reference

12 December 2020

Limited value of temporal artery ultrasonography examinations for diagnosis of giant cell arteritis: analysis of 77 subjects

1 reference

12 December 2020

The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-94.

1 reference

12 December 2020

Clinical features of GCA/PMR.

1 reference

12 December 2020

Vasculitis in the geriatric population

1 reference

12 December 2020

Cervical interspinous bursitis in active polymyalgia rheumatica

1 reference

12 December 2020

10.2165/11592500-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1041498605

0 references

1 reference